Troy Cox, Steven Kafka, Konstantin Fiedler
Steven Kafka will resign as president and chief operating officer of Foundation Medicine, effective Feb. 16, 2018. CEO Troy Cox will take on the additional role of president, and Konstantin Fiedler will become COO. Fiedler joined the company in 2016 as senior vice president of international markets and managing director of FMI Germany, the firm's wholly-owned subsidiary in Germany. Prior to that, he served as head of innovation of the healthcare unit of Linde and managing director in the Leica Biosystems division of Danaher. He also served as a general manager in General Electric's life sciences division.
Randy Scott
Invitae Chairman Randy Scott has joined the board of directors of cancer early detection firm Freenome, which also includes the company's CEO Gabriel Otte, Chief Operating Officer Riley Ennis, and Vijay Pande general partner at Andreessen Horowitz. Scott cofounded Incyte in 1991, where he served as chairman, CSO, and president. In 2000, he cofounded and led Genomic Health, and in 2012, he became CEO of Invitae before his appointment as executive chairman this year.
Kareem Saad
Sema4 has appointed Kareem Saad as chief strategy officer. Saad previously served as chief commercial officer and executive vice president of strategy and business development for Source Medical Solutions. Before that, he was a director in Dell's Healthcare and Life Sciences division. He has also held a number of excutive leadership roles at mid-size and early-stage biotech and healthcare IT companies, and began his career by cofounding InphoGene Bionformatics.
For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.
